ROCHE HOLDING AG-BR (RHO.DE) Stock Price & Overview

FRA:RHO • CH0012032113

Current stock price

353.4 EUR
+1.8 (+0.51%)
Last:

The current stock price of RHO.DE is 353.4 EUR. Today RHO.DE is up by 0.51%. In the past month the price decreased by -13.42%.

RHO.DE Key Statistics

1-Month Range333 - 411.8
Current RHO.DE stock price positioned within its 1-month range.
Market Cap
285.989B
P/E
16.54
Fwd P/E
15.75
EPS (TTM)
21.37
Dividend Yield
3.13%

RHO.DE Stock Performance

Today
+0.51%
1 Week
+3.33%
1 Month
-13.42%
3 Months
-3.50%
Longer-term
6 Months +9.68%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

RHO.DE Stock Chart

ROCHE HOLDING AG-BR / RHO Daily stock chart

RHO.DE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to RHO.DE.


Chartmill TA Rating
Chartmill Setup Rating

RHO.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to RHO.DE. RHO.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RHO.DE Earnings

On January 29, 2026 RHO.DE reported an EPS of 8.53 and a revenue of 30.57B. The company missed EPS expectations (-3.53% surprise) and missed revenue expectations (-3.25% surprise).

Next Earnings DateApr 23, 2026
Last Earnings DateJan 29, 2026
PeriodQ4 / 2025
EPS ReportedCHF8.53
Revenue Reported30.572B
EPS Surprise -3.53%
Revenue Surprise -3.25%

RHO.DE Forecast & Estimates

29 analysts have analysed RHO.DE and the average price target is 400.71 EUR. This implies a price increase of 13.39% is expected in the next year compared to the current price of 353.4.

For the next year, analysts expect an EPS growth of 5.01% and a revenue growth 1.49% for RHO.DE


Analysts
Analysts70.34
Price Target400.71 (13.39%)
EPS Next Y5.01%
Revenue Next Year1.49%

RHO.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

RHO.DE Financial Highlights

Over the last trailing twelve months RHO.DE reported a non-GAAP Earnings per Share(EPS) of 21.37. The EPS increased by 4.41% compared to the year before.


Income Statements
Revenue(TTM)61.52B
Net Income(TTM)12.88B
Industry RankSector Rank
PM (TTM) 20.94%
ROA 12.79%
ROE 38.1%
Debt/Equity 0.85
Chartmill High Growth Momentum
EPS Q2Q%-0.47%
Sales Q2Q%-0.24%
EPS 1Y (TTM)4.41%
Revenue 1Y (TTM)1.69%

RHO.DE Ownership

Ownership
Inst Owners41.39%
Shares809.25M
Float688.92M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About RHO.DE

Company Profile

RHO logo image Roche Holding AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Basel, Basel-Stadt and currently employs 112,774 full-time employees. The company went IPO on 2001-05-04. Roche Holding AG (Roche) is a research-based healthcare company. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Company Info

IPO: 2001-05-04

ROCHE HOLDING AG-BR

Grenzacherstr. 124

Basel BASEL-STADT CH

Employees: 112774

RHO Company Website

RHO Investor Relations

Phone: 41616881111

ROCHE HOLDING AG-BR / RHO.DE FAQ

Can you describe the business of ROCHE HOLDING AG-BR?

Roche Holding AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Basel, Basel-Stadt and currently employs 112,774 full-time employees. The company went IPO on 2001-05-04. Roche Holding AG (Roche) is a research-based healthcare company. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.


What is the stock price of ROCHE HOLDING AG-BR today?

The current stock price of RHO.DE is 353.4 EUR. The price increased by 0.51% in the last trading session.


Does ROCHE HOLDING AG-BR pay dividends?

ROCHE HOLDING AG-BR (RHO.DE) has a dividend yield of 3.13%. The yearly dividend amount is currently 0.


What is the ChartMill rating of ROCHE HOLDING AG-BR stock?

RHO.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the GICS sector and industry of RHO stock?

ROCHE HOLDING AG-BR (RHO.DE) operates in the Health Care sector and the Pharmaceuticals industry.


How many employees does ROCHE HOLDING AG-BR have?

ROCHE HOLDING AG-BR (RHO.DE) currently has 112774 employees.


What is the next earnings date for RHO stock?

ROCHE HOLDING AG-BR (RHO.DE) will report earnings on 2026-04-23.